Written by Admin | Apr 22, 2020
Aetion® and HealthVerity have launched a new set of tools for biopharma companies and regulators looking to assess new COVID-19 treatments, according to a MobiHealthNews report. Aetion CEO Carolyn Magill, in a statement, said, “Our offerings use HealthVerity’s comprehensive, real-time data to obtain decision-ready insights that can help meet the need for accelerated approvals and access while maintaining our high bar for evidence to support critical safety and effectiveness determinations.”
Read More